Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up

Purpose: To evaluate the treatment solutions and effectiveness of intravitreal ranibizumab (RBZ) or conbercept in patients with wet age-related macular degeneration (wAMD) in a real-life setting in China.Methods: The medical records of 368 patients with wAMD who started RBZ or conbercept treatment b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yan Lu, Wenzhi Huang, Yuehong Zhang, Xiongfei Huang, Xu Zhang, Haizhi Ma, Guoliang Ren, Feng Shi, Lihui Kuang, Shigang Yan, Shuke Luo, Junyan Zhang, Jingfang He, Weizhong Yang, Zongyin Gao, Yunxia Leng
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	age-related macular degeneration ranibizumab conbercept polypoidal choroidal vasculopathy (PCV) choroidal neovascularization (CNV) Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ac9e16d329af4ba2be07b0a004af0630
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ac9e16d329af4ba2be07b0a004af0630
record_format	dspace
spelling	oai:doaj.org-article:ac9e16d329af4ba2be07b0a004af06302021-11-11T07:32:02ZFactors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up2296-858X10.3389/fmed.2021.735318https://doaj.org/article/ac9e16d329af4ba2be07b0a004af06302021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.735318/fullhttps://doaj.org/toc/2296-858XPurpose: To evaluate the treatment solutions and effectiveness of intravitreal ranibizumab (RBZ) or conbercept in patients with wet age-related macular degeneration (wAMD) in a real-life setting in China.Methods: The medical records of 368 patients with wAMD who started RBZ or conbercept treatment between 1 May 2014 and 30 April 2018 were evaluated. All patients were defined on fundus angiography at baseline to determine the subtype of AMD (PCV or CNV). We report visual acuity (VA) and central retinal thickness (CRT) measurements at baseline and 12 months.Results: The average number of anti-VEGF injections was 2.1 ± 1.2. The BCVA improvement of these two groups was similar with a difference of 1.00 letter (95% CI: −1.4~3.4, p = 0.8505). At the end of the study, a BCVA increase of at least 5 letters was determined to be a satisfactory efficacy endpoint. Several factors were related to the possible improvement in the satisfactory efficacy endpoint, including female sex (OR 2.07, 95% CI 1.22~3.51), number of injections (OR 1.40, 95% CI 1.12~1.75) and VA change at the first month (OR 13.75, 95% CI 7.41~25.51). Additionally, some factors were related to the possible reduction in the satisfactory efficacy endpoint, including diabetes (OR 0.27, 95% CI 0.10~0.73) and disease history (OR 0.75, 95% CI 0.57~0.98).Conclusion: Our study demonstrates that anti-VEGF drugs can effectively improve BCVA and reduce CRT in AMD patients. Sex, number of injections, VA change at the first month, diabetes and disease history are the most important factors affecting visual acuity.Yan LuWenzhi HuangYuehong ZhangXiongfei HuangXu ZhangHaizhi MaGuoliang RenFeng ShiLihui KuangShigang YanShuke LuoJunyan ZhangJingfang HeWeizhong YangZongyin GaoYunxia LengFrontiers Media S.A.articleage-related macular degenerationranibizumabconberceptpolypoidal choroidal vasculopathy (PCV)choroidal neovascularization (CNV)Medicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	age-related macular degeneration ranibizumab conbercept polypoidal choroidal vasculopathy (PCV) choroidal neovascularization (CNV) Medicine (General) R5-920
spellingShingle	age-related macular degeneration ranibizumab conbercept polypoidal choroidal vasculopathy (PCV) choroidal neovascularization (CNV) Medicine (General) R5-920 Yan Lu Wenzhi Huang Yuehong Zhang Xiongfei Huang Xu Zhang Haizhi Ma Guoliang Ren Feng Shi Lihui Kuang Shigang Yan Shuke Luo Junyan Zhang Jingfang He Weizhong Yang Zongyin Gao Yunxia Leng Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
description	Purpose: To evaluate the treatment solutions and effectiveness of intravitreal ranibizumab (RBZ) or conbercept in patients with wet age-related macular degeneration (wAMD) in a real-life setting in China.Methods: The medical records of 368 patients with wAMD who started RBZ or conbercept treatment between 1 May 2014 and 30 April 2018 were evaluated. All patients were defined on fundus angiography at baseline to determine the subtype of AMD (PCV or CNV). We report visual acuity (VA) and central retinal thickness (CRT) measurements at baseline and 12 months.Results: The average number of anti-VEGF injections was 2.1 ± 1.2. The BCVA improvement of these two groups was similar with a difference of 1.00 letter (95% CI: −1.4~3.4, p = 0.8505). At the end of the study, a BCVA increase of at least 5 letters was determined to be a satisfactory efficacy endpoint. Several factors were related to the possible improvement in the satisfactory efficacy endpoint, including female sex (OR 2.07, 95% CI 1.22~3.51), number of injections (OR 1.40, 95% CI 1.12~1.75) and VA change at the first month (OR 13.75, 95% CI 7.41~25.51). Additionally, some factors were related to the possible reduction in the satisfactory efficacy endpoint, including diabetes (OR 0.27, 95% CI 0.10~0.73) and disease history (OR 0.75, 95% CI 0.57~0.98).Conclusion: Our study demonstrates that anti-VEGF drugs can effectively improve BCVA and reduce CRT in AMD patients. Sex, number of injections, VA change at the first month, diabetes and disease history are the most important factors affecting visual acuity.
format	article
author	Yan Lu Wenzhi Huang Yuehong Zhang Xiongfei Huang Xu Zhang Haizhi Ma Guoliang Ren Feng Shi Lihui Kuang Shigang Yan Shuke Luo Junyan Zhang Jingfang He Weizhong Yang Zongyin Gao Yunxia Leng
author_facet	Yan Lu Wenzhi Huang Yuehong Zhang Xiongfei Huang Xu Zhang Haizhi Ma Guoliang Ren Feng Shi Lihui Kuang Shigang Yan Shuke Luo Junyan Zhang Jingfang He Weizhong Yang Zongyin Gao Yunxia Leng
author_sort	Yan Lu
title	Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
title_short	Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
title_full	Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
title_fullStr	Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
title_full_unstemmed	Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
title_sort	factors for visual acuity improvement after anti-vegf treatment of wet age-related macular degeneration in china: 12 months follow up
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/ac9e16d329af4ba2be07b0a004af0630
work_keys_str_mv	AT yanlu factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT wenzhihuang factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT yuehongzhang factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT xiongfeihuang factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT xuzhang factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT haizhima factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT guoliangren factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT fengshi factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT lihuikuang factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT shigangyan factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT shukeluo factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT junyanzhang factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT jingfanghe factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT weizhongyang factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT zongyingao factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup AT yunxialeng factorsforvisualacuityimprovementafterantivegftreatmentofwetagerelatedmaculardegenerationinchina12monthsfollowup
_version_	1718439428300472320

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up

Ejemplares similares